[Erectile dysfunction in primary care as possible marker of health status: associated factors and response to sildenafil].
OBJECTIVE
To find the factors linked to erectile dysfunction, to evaluate this as a possible marker of health status, to analyse the evolution of clinical parameters of associated illnesses and the response to Viagra.Design. Intervention study without a control.


METHODS
Alguazas Health Centre (Murcia).


METHODS
All the patients in the programme (125), with a figure on the sexual health in men index (SHIM) below 21.Interventions. Health education and administration of Viagra.


METHODS
Concomitant illnesses, pathologies previously unknown to the patient, changes in erectile function valued on the international index of erectile function (IIEF), and changes in blood pressure, glucaemia and lipids.


RESULTS
Factors linked to erectile dysfunction were diabetes (50.4%), hypertension (33.6%), hypercholesterolaemia (22.4%), urological pathology (12.8%) and mental health disorders (33.6%). The hidden pathology detected was 15 cases of hypertension, 3 diabetes, 2 cardiopathies, 20 dyslipaemias, 3 depressions, 13 anxiety and 5 urological problems. The variations in clinical parameters at 3 months were: glucaemia, -38.3 mg (P<.001, Student s t=-5.186); HbA1c, -0.9 (P<.05, Student s t=-2.16); systolic blood pressure, -16 mm Hg (P<.01, Student s t=-3.486) and diastolic pressure -13 mm Hg (P<.001, Student s t=-4.594); and total cholesterol, -14.2% (P<.001, Student s t=7.01). Erectile function improved by 74% with Viagra.


CONCLUSIONS
2 out of every 3 patients with erectile dysfunction presented associated diseases; one in every 3 were ignorant of their health problem. Monitoring of chronic illnesses improved significantly. Finally, 3 in every 4 responded to Viagra.
Guirao Sánchez
L
L
Centro de Salud de Alguazas. Gerencia de Atención Primaria de Murcia. Spain.
García-Giralda Ruiz
L
L
Sandoval Martínez
C
C
Mocciaro Loveccio
A
A
D000328:Adult; D000367:Age Factors; D000368:Aged; D001007:Anxiety / Q000150:complications; D003627:Data Interpretation, Statistical; D003863:Depression / Q000150:complications; D048909:Diabetes Complications; D007172:Erectile Dysfunction / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D006304:Health Status; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D012307:Risk Factors; D000068677:Sildenafil Citrate; D013450:Sulfones; D014570:Urologic Diseases / Q000150:complications; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate